Skip to main content
. 2020 Oct 16;216:107706. doi: 10.1016/j.pharmthera.2020.107706

Fig. 1.

Fig. 1

Artemisinins: multiple modes of action against cancer CDK2/4/6; Cyclin dependent kinase 2/4/6:mTOR; mammalian target of rapamycin: EGFR;epidermal growth factor: HIF---1α; Hypoxia Inducible Factor 1 alpha:VEGF; Vascular endothelial growth factor: KDR/flk---1;kinase insert domain receptor MMP2; Matrix Metallopeptidase 2: TIMP---2; Tissue inhibitor of metalloproteinases 2: NCAM; Neural Cell Adhesion Molecule: IL---6;interleukin---6: IL---1β; Interleukin---1β: TNF---α; Tumour necrosis factor---α: TGF---β1; Transforming growth factor beta 1: NF---κB; nuclear factor kappa---light---chain--- enhancer of activated B cells: MIP---2; Macrophage Inflammatory Protein 2: PGE2; Prostaglandin E2: NO;Nitric Oxide.